[go: up one dir, main page]

MX2018011025A - Metodos para tratar o prevenir la enfermedad del injerto contra huésped. - Google Patents

Metodos para tratar o prevenir la enfermedad del injerto contra huésped.

Info

Publication number
MX2018011025A
MX2018011025A MX2018011025A MX2018011025A MX2018011025A MX 2018011025 A MX2018011025 A MX 2018011025A MX 2018011025 A MX2018011025 A MX 2018011025A MX 2018011025 A MX2018011025 A MX 2018011025A MX 2018011025 A MX2018011025 A MX 2018011025A
Authority
MX
Mexico
Prior art keywords
treating
methods
host disease
versus host
graft versus
Prior art date
Application number
MX2018011025A
Other languages
English (en)
Inventor
A Sachs Jessica
E Ford John
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2018011025A publication Critical patent/MX2018011025A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un método para tratar o prevenir la GcHD en un paciente humano, que compr3ende administrarle a un paciente que padece GvHD o está en riesgo de GvHD, un anticuerpo humanizado que tenga especificidad de unión a la integrina a4ß7 humana.
MX2018011025A 2016-03-14 2017-03-13 Metodos para tratar o prevenir la enfermedad del injerto contra huésped. MX2018011025A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US201662420825P 2016-11-11 2016-11-11
PCT/US2017/022067 WO2017160700A1 (en) 2016-03-14 2017-03-13 Methods of treating or preventing graft versus host disease

Publications (1)

Publication Number Publication Date
MX2018011025A true MX2018011025A (es) 2019-01-10

Family

ID=58455657

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011025A MX2018011025A (es) 2016-03-14 2017-03-13 Metodos para tratar o prevenir la enfermedad del injerto contra huésped.
MX2024008740A MX2024008740A (es) 2016-03-14 2018-09-12 Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024008740A MX2024008740A (es) 2016-03-14 2018-09-12 Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.

Country Status (12)

Country Link
US (1) US20190077868A1 (es)
EP (1) EP3430053A1 (es)
JP (3) JP2019512493A (es)
KR (2) KR102667332B1 (es)
CN (2) CN117298268A (es)
AU (2) AU2017234010B2 (es)
BR (1) BR112018068625A2 (es)
CA (1) CA3017758A1 (es)
IL (1) IL261767A (es)
MA (1) MA43755A (es)
MX (2) MX2018011025A (es)
WO (1) WO2017160700A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44408A (fr) * 2016-03-14 2019-01-23 Millennium Pharm Inc Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
EP3468597A1 (en) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
KR20190141148A (ko) * 2017-04-28 2019-12-23 밀레니엄 파머슈티컬스 인코퍼레이티드 소아 장애를 치료하는 방법
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
NZ536504A (en) 2002-05-24 2008-04-30 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
DE60314175T2 (de) 2002-11-18 2008-01-24 Chemocentryx Inc., Mountain View Arylsulfonamide
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
KR101364276B1 (ko) 2004-09-03 2014-02-20 제넨테크, 인크. 인간화 항-베타７ 길항제 및 그의 용도
EP1940827B1 (en) * 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3311834A1 (en) 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
KR20180041229A (ko) * 2015-08-25 2018-04-23 유에이비 리서치 파운데이션 줄기 세포 이식을 위한 방법
MA44408A (fr) * 2016-03-14 2019-01-23 Millennium Pharm Inc Méthode de traitement de la réaction du greffon contre l'hôte (gvd)

Also Published As

Publication number Publication date
CN117298268A (zh) 2023-12-29
CA3017758A1 (en) 2017-09-21
KR20180117195A (ko) 2018-10-26
MA43755A (fr) 2018-11-28
KR102830639B1 (ko) 2025-07-07
JP2019512493A (ja) 2019-05-16
BR112018068625A2 (pt) 2019-07-30
KR20240074903A (ko) 2024-05-28
IL261767A (en) 2018-10-31
EP3430053A1 (en) 2019-01-23
JP2025118642A (ja) 2025-08-13
JP2022137024A (ja) 2022-09-21
US20190077868A1 (en) 2019-03-14
WO2017160700A1 (en) 2017-09-21
AU2017234010B2 (en) 2024-06-13
AU2017234010A1 (en) 2018-09-27
AU2024203289A1 (en) 2024-08-01
MX2024008740A (es) 2024-07-23
KR102667332B1 (ko) 2024-05-20
CN109153721A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
MX2022002504A (es) Anticuerpos para cd40.
PH12020552229A1 (en) Il-11ra antibodies
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
PH12014500903A1 (en) Bispecific immunobinders directed against tnf and il-17
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2020008122A (es) Anticuerpos anti-pd-1.
MX392496B (es) Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica.
MX2024008740A (es) Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.
MX2025001934A (es) UN ANTICUERPO HUMANIZADO QUE TIENE ESPECIFICIDAD DE UNIÓN PARA LA INTEGRINA A4ß7 HUMANA PARA USARSE EN LA PREVENCIÓN O REDUCCIÓN DE LA APARICIÓN DE GVHD AGUDA EN UN PACIENTE HUMANO QUE TIENE ALL O AML Y QUE SE SOMETE A ALLO-HSCT
MX2020005473A (es) Anticuerpos humanizados que se dirigen al factor tisular humano.
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid